Literature DB >> 19228154

Follow-up default in a hospital-based universal newborn hearing screening programme in a low-income country.

B O Olusanya1.   

Abstract

BACKGROUND: Effective early detection of infants with permanent hearing impairment requires parental compliance with various stages of a screening protocol. However, many infants who failed initial screening tests are often not presented for follow-up evaluation, thus compromising prospects for early detection and intervention. This study set out to determine maternal and infant factors associated with loss to follow-up in a hospital-based universal hearing screening programme in a low-income country.
METHODS: A cross-sectional study in which babies in a tertiary maternity hospital were enrolled into a two-stage hearing screening programme with transient-evoked otoacoustic emissions followed by automated auditory brainstem response (AABR) for all transient-evoked otoacoustic emissions referrals before hospital discharge. Diagnostic evaluation was scheduled for AABR referrals on outpatient basis. Correlates of non-compliance were determined through multivariable logistic regression analyses of relevant maternal and infant factors.
RESULTS: Some 1330 babies participated in the first-stage screening and of 551 scheduled for AABR; 56 (10.2%) did not complete. Some 37 (84.1%) of the 44 AABR referrals did not complete the diagnostic evaluation. There were no significant differences between the profile of those who did not complete either the second-stage screening or diagnostic evaluation and those who completed across virtually all socio-demographic factors except that Christian mothers were significantly more likely not to complete the second-stage screening than diagnostic evaluation compared with their Muslim counterparts (odds ratio: 3.01; 95% confidence intervals: 1.17-7.87). The only independent predictors of non-compliance with pre-discharge screening were delivery by spontaneous vertex (odds ratio: 2.76; 95% confidence intervals: 1.47-5.19) and admission into special care baby unit (odds ratio: 5.62; 95% confidence intervals: 2.92-10.84) while no factor was predictive of non-compliance with diagnostic evaluation.
CONCLUSIONS: Mode of delivery or having high-risk baby influences compliance before hospital discharge while factors other than maternal or infant socio-demographic/medical profile such as unfavourable cultural beliefs and stigma may be key determinants of follow-up compliance after discharge.

Entities:  

Mesh:

Year:  2009        PMID: 19228154     DOI: 10.1111/j.1365-2214.2008.00923.x

Source DB:  PubMed          Journal:  Child Care Health Dev        ISSN: 0305-1862            Impact factor:   2.508


  5 in total

1.  Neonatal hearing screening in remote areas of China: a comparison between rural and urban populations.

Authors:  Wu Wenjin; Tang Xiangrong; Li Yun; Lü Jingrong; Chen Jianyong; Wang Xueling; Huang Zhiwu; Wu Hao
Journal:  J Int Med Res       Date:  2017-06-12       Impact factor: 1.671

2.  The hearing screening experiences and practices of primary health care nurses: Indications for referral based on high-risk factors and community views about hearing loss.

Authors:  Nasim B Khan; Lavanithum Joseph; Miriam Adhikari
Journal:  Afr J Prim Health Care Fam Med       Date:  2018-10-10

3.  Factors Affecting Neonatal Hearing Screening Follow-up in Developing Countries: One Insitution Prospective Pilot Study.

Authors:  Nermin Hrncic; Amna Goga; Selma Hrncic; Haris Hatibovic; Djenad Hodzic
Journal:  Medeni Med J       Date:  2021-03-26

4.  Protocol and programme factors associated with referral and loss to follow-up from newborn hearing screening: a systematic review.

Authors:  Allison R Mackey; Andrea M L Bussé; Valeria Del Vecchio; Elina Mäki-Torkko; Inger M Uhlén
Journal:  BMC Pediatr       Date:  2022-08-05       Impact factor: 2.567

5.  Audiological follow-up in a risk-based newborn hearing screening programme: An exploratory study of the influencing factors.

Authors:  Amisha Kanji; Kirsten Krabbenhoft
Journal:  S Afr J Commun Disord       Date:  2018-10-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.